HNSA — Hansa Biopharma AB Income Statement
0.000.00%
Last trade - 00:00
- SEK1.54bn
- SEK1.95bn
- SEK134.09m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.36 | 6.1 | 33.9 | 155 | 134 |
Cost of Revenue | |||||
Gross Profit | 2.5 | 5.1 | 18.5 | 116 | 71 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 363 | 429 | 581 | 743 | 923 |
Operating Profit | -360 | -423 | -547 | -589 | -788 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -360 | -421 | -548 | -610 | -831 |
Provision for Income Taxes | |||||
Net Income After Taxes | -360 | -421 | -548 | -611 | -832 |
Net Income Before Extraordinary Items | |||||
Net Income | -360 | -421 | -548 | -611 | -832 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -360 | -421 | -548 | -611 | -832 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -9 | -9.98 | -12.3 | -13.6 | -15.8 |
Dividends per Share |